Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan

Hori, Masatsugu; Ikeda, Shunya; Okumura, Ken; Matsuda, Shinya; Koretsune, Yukihiro; Montouchet, C.; Watanabe-Fujinuma, Emi; Evers, Thomas; Rossi, B; Ruff, L.; Brière, J

doi:10.1080/13696998.2016.1182919

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for these limitations is that rivaroxaban fine granules have not been available until recently, and the fine granules were not used widely even in Japan. Rivaroxaban fine granules are not used in many rehabilitation hospitals in Japan due to the high cost, although rivaroxaban may decrease NVAF events and decrease overall medical costs in Japan [26]. Another reason is that, in rehabilitation hospitals, anticoagulants for patients with NVAF may be switched to warfarin or rivaroxaban with crushed tablets or to tablets when swallowing disorders improved.…”

Section: Discussionmentioning

confidence: 99%

Rivaroxaban concentrations in acute stroke patients with different dosage forms

et al. 2019

View full text Add to dashboard Cite

BackgroundThe crushed-tablet rivaroxaban concentration has been previously reported to be lower than the non-crushed concentration. However, the rivaroxaban concentration of fine granules has not yet been investigated. The anticoagulation intensity of rivaroxaban with fine granules, tablets, and crushed tablets was compared in acute stroke patients to assess the efficacy of each form.Methods and findingsHospitalized patients over 75 years old with acute stroke who started taking rivaroxaban from April 2012 to September 2017 were included. Blood samples were drawn just before and 4 hours after taking rivaroxaban on a median of 5 days after treatment initiation for concentration measurements (C0h, C4h) based on an anti-factor Xa chromogenic assay. Of 114 patients (49 female, 83±5 years old), 97 had ischemic strokes, 9 had transient ischemic attacks, and 8 had intracerebral hemorrhages. Rivaroxaban was administered a median of 7 days after onset. Of these, 38 patients were given the 15 mg dose, and 76 were given the 10 mg dose. In the 15 mg dose group, C0h was significantly higher in the fine granule group than in the crushed tablet group, with no significant difference compared to the tablet group [C0h: 27.6±6.8 vs 4.0±4.1 (P = 0.01) vs. 33.3±25.2 ng/ml, (P = 0.51), respectively], as was C4h [223.0±66.6 vs 103.0±79.5 (P = 0.02) vs. 229.5±121.6 ng/ml (P = 0.88)]. In the 10 mg dose group, C0h was significantly higher in the fine granule group than in the crushed tablet group and comparable to that in the tablet group [23.2±7.9 vs 7.5±6.2 (P<0.01) vs 19.0±15.8 ng/ml, (P = 0.35)], as was C4h [150.7±85.4 vs 85.1±46.8 (P<0.01) vs 189.8±92.7 ng/ml (P = 0.18)].ConclusionsThe rivaroxaban concentration with fine granules was consistent with that in the tablet group and higher than that in the crushed tablet group.

show abstract

Section: Discussionmentioning

confidence: 99%

Rivaroxaban concentrations in acute stroke patients with different dosage forms

et al. 2019

View full text Add to dashboard Cite

show abstract

The budget impact of implementing atrial fibrillation-screening in European countries

Eklund,

Bernfort,

Appelberg

et al. 2024

European Heart Journal Supplements

View full text Add to dashboard Cite

A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers’ costs, introducing population screening for AF will result in savings of stroke-related costs.

show abstract

Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan

Cited by 2 publications

References 49 publications

Rivaroxaban concentrations in acute stroke patients with different dosage forms

Rivaroxaban concentrations in acute stroke patients with different dosage forms

The budget impact of implementing atrial fibrillation-screening in European countries

Contact Info

Product

Resources

About